메뉴 건너뛰기
Gynecologic Oncology
Volumn 124, Issue 1, 2012, Pages 171-
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;
EID: 83055173012     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.07.007     Document Type: Letter
Times cited : (5)
References (5)
  • 1
    • 79955477996 scopus 로고    scopus 로고
    • Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    • D.M. O'Malley, D.L. Richardson, and P.S. Rheaume Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer Gynecol Oncol 121 2011 269 272
    • (2011) Gynecol Oncol , vol.121 , pp. 269-272
    • O'Malley, D.M.1    Richardson, D.L.2    Rheaume, P.S.3
  • 2
    • 77954499682 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: A Gynecologic Oncology Group study
    • (LBA 1)
    • R.A. Burger, M.F. Brady, and M.A. Bookman Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: a Gynecologic Oncology Group study J Clin Oncol 18s 2010 946s (LBA 1)
    • (2010) J Clin Oncol , vol.18 S
    • Burger, R.A.1    Brady, M.F.2    Bookman, M.A.3
  • 3
    • 79953893326 scopus 로고    scopus 로고
    • At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis
    • D.E. Cohn, K.H. Kim, and K.E. Resnick At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis J Clin Oncol 29 2011 1247 1251
    • (2011) J Clin Oncol , vol.29 , pp. 1247-1251
    • Cohn, D.E.1    Kim, K.H.2    Resnick, K.E.3
  • 4
    • 80053229517 scopus 로고    scopus 로고
    • OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    • (LBA 5007)
    • C. Aghajanian, N.J. Finkler, and T. Rutherford OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 29 18 s, part II of II 2011 781s (LBA 5007)
    • (2011) J Clin Oncol , vol.29 , Issue.18 PART II OF II
    • Aghajanian, C.1    Finkler, N.J.2    Rutherford, T.3
  • 5
    • 79960440858 scopus 로고    scopus 로고
    • Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown
    • M. Markman Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown Gynecol Oncol 122 2011 213 214
    • (2011) Gynecol Oncol , vol.122 , pp. 213-214
    • Markman, M.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.